International Study to Predict Optimised Treatment - in Depression
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.
- drug : Escitalopram
- drug : Venlafaxine-XR
- drug : Sertraline
Phase: Phase 4
Ages Eligible For Study:
- Meet DSM-IV criteria for primary diagnosis of MDD. - HAM-D17 score of ? 16. - 18-65 years age-range - Subjects with English or Dutch literacy and fluency. - Written, informed consent.